Article PDF
Avoid common mistakes on your manuscript.
References
Kotloff KL, Dale JB: Progress in group A streptococcal vaccine development. Pediatr Infect Dis J 2004, 23:765–766.
Massell BF, Honikman LH, Amezcua J: Rheumatic fever following streptococcal vaccination: report of three cases. JAMA 1969, 207:1115–1159.
Batzloff MR, Hayman WA, Davies MR, et al.: Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid specific antibodies to protection. J Infect Dis 2003, 187:1598–1608.
Halperin SA, Smith B, Russell M, et al.: An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000, 18:1312–1319.
Halperin SA, Scheifele D, Mills E, et al.: Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 2003, 21:2298–2306.
Shulman ST, Tanz RR, Kabat W, et al.: Group A streptococcal pharyngitis serotype surveillance in North America. Clin Infect Dis 2004, 39:325–332.
Schuchat A, Hilger T, Zell E, et al.: Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001, 7:92–99.
Stollerman GH: Rheumatic fever. Lancet 1997, 349:935–942.
Rights and permissions
About this article
Cite this article
Brook, I. Safety and immunogenicity of 26-valent group a streptococcus vaccine. Curr Infect Dis Rep 8, 179–180 (2006). https://doi.org/10.1007/s11908-006-0056-y
Issue Date:
DOI: https://doi.org/10.1007/s11908-006-0056-y